SightfileU.S. market data from official filings

Companies › KALV

KALVISTA PHARMACEUTICALS INC (KALV)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001348911 · EDGAR filings · Updated 2026-06-22

KALVISTA PHARMACEUTICALS INC (KALV) has reported institutional ownership of 135.2%, with 183 institutional managers holding positions valued at $1.39B per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01).

Institutional ownership
135.2%
Institutional managers
183
Reported 13F value
$1.39B
Insider activity
97 trans.
−$6.75M net selling
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, KALVISTA PHARMACEUTICALS INC has 183 institutional holders and institutional ownership of 135.2%.

Insider activity

Insiders reported 97 transactions (1 buys, 47 sells) across 6 reporting insiders, with a net reported value of −$6.75M.

Data flags from SEC filings

Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2026-06-11 (recurring since 2026-06-11) — source filing. The authoritative details are those stated in the filing itself.

Related companies

INTELLIA THERAPEUTICS INC (NTLA) · Procept Biorobotics Corp (PRCT) · BICARA THERAPEUTICS INC (BCAX) · PROGYNY INC (PGNY) · IMMUNITYBIO INC (IBRX) · QUIDELORTHO CORP (QDEL)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-22.